Floatz logo

Apixaban

Transient Ischemic Attack

Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de QuebecSmall moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the Transient Ischemic Attack cohort.

Asset / SponsorPhaseRating
CLOPIDOGREL
Sichuan Provincial People's Hospital
Phase 4BBB
Aspirin
Sichuan Provincial People's Hospital
Phase 4BBB
Ticagrelor
Mazandaran University of Medical Sciences
Phase 3BBB
Cilostazol
Stanford University
Phase 4BBB
Rivaroxaban
General Hospital of Shenyang Military Region
Phase 4BBB

View all 42 →

Same molecule, other indications

Apixaban is also rated in:

venous thromboembolismActive
BBB
Indicative · Phase 4
79 / 100
View asset →
atrial fibrillationActive
BBB
Indicative · Phase 4
77 / 100
View asset →
thrombotic diseaseActive
BB
Indicative · Phase 4
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →